John Marshall




Dr. John Marshall is a Professor of Surgery at the University of Toronto, and an Intensivist at St. Michael’s Hospital in Toronto, Canada.  His academic interests are sepsis, trauma, and the innate immune response.  His laboratory studies the cellular mechanisms that prolong neutrophil survival in critical illness by preventing neutrophil programmed cell death, or apoptosis.  Professor Marshall has an active clinical research interest in sepsis and Intensive Care Unit-acquired infection, and in the design of clinical trials and outcome measures.  He has published 440 manuscripts, and 85 book chapters, and is the editor of 2 books.  He is the founding chair of the International Forum of Acute Care Trialists (InFACT) – a global network of investigator-led critical care clinical research groups, and past Secretary-General of the World Federation of Societies of Intensive and Critical Care Medicine.  He co-chairs the WHO R&D Working Group on the Clinical Characterization and Management of COVID-19.  He is past-chair of the International Sepsis Forum, past-President of the Surgical Infection Society, and past-chair of the Canadian Critical Care Trials Group.  He has given invited lectures at more than 540 meetings around the world, and is an Associate Editor of the journals Critical Care Medicine and Critical care.”

Recent Publications

  1. Heels-Ansdell, D, Billot, L, Thabane, L, Alhazzani, W, Deane, A, Guyatt, G et al.. REVISE: re-evaluating the inhibition of stress erosions in the ICU-statistical analysis plan for a randomized trial. Trials. 2023;24 (1):796. doi: 10.1186/s13063-023-07794-z. PubMed PMID:38057875 PubMed Central PMC10701941.
  2. Soussi, S, Ahmadiankalati, M, Jentzer, JC, Marshall, JC, Lawler, PR, Herridge, M et al.. Clinical phenotypes of cardiogenic shock survivors: insights into late host responses and long-term outcomes. ESC Heart Fail. 2023; :. doi: 10.1002/ehf2.14596. PubMed PMID:38050658 .
  3. Mohammed, Y, Tran, K, Carlsten, C, Ryerson, C, Wong, A, Lee, T et al.. Proteomic Evolution from Acute to Post-COVID-19 Conditions. J Proteome Res. 2023; :. doi: 10.1021/acs.jproteome.3c00324. PubMed PMID:38048423 .
  4. Banoei, MM, McIntyre, LA, Stewart, DJ, Mei, SHJ, Courtman, D, Watpool, I et al.. Metabolomics Analysis of Mesenchymal Stem Cell (MSC) Therapy in a Phase I Clinical Trial of Septic Shock: An Exploratory Study. Metabolites. 2023;13 (11):. doi: 10.3390/metabo13111142. PubMed PMID:37999238 PubMed Central PMC10673547.
  5. Deane, AM, Alhazzani, W, Guyatt, G, Finfer, S, Marshall, JC, Myburgh, J et al.. REVISE: Re-Evaluating the Inhibition of Stress Erosions in the ICU: a randomised trial protocol. BMJ Open. 2023;13 (11):e075588. doi: 10.1136/bmjopen-2023-075588. PubMed PMID:37968012 PubMed Central PMC10660838.
  6. REMAP-CAP Investigators, Hills, TE, Lorenzi, E, Berry, LR, Shyamsundar, M, Al-Beidh, F et al.. Simvastatin in Critically Ill Patients with Covid-19. N Engl J Med. 2023; :. doi: 10.1056/NEJMoa2309995. PubMed PMID:37888913 .
  7. LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Adhikari, NKJ, Hashmi, M, Tirupakuzhi Vijayaraghavan, BK, Haniffa, R, Beane, A et al.. Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. JAMA. 2023;330 (18):1745-1759. doi: 10.1001/jama.2023.21407. PubMed PMID:37877585 PubMed Central PMC10600726.
  8. Shaw, JF, Ouyang, Y, Fergusson, DA, McArdle, T, Martin, C, Cook, D et al.. A Hospital-Wide Open-Label Cluster Crossover Pragmatic Comparative Effectiveness Randomized Trial Comparing Normal Saline to Ringer's Lactate: Protocol and Statistical Analysis Plan of The FLUID Trial. JMIR Res Protoc. 2023;12 :e51783. doi: 10.2196/51783. PubMed PMID:37801356 PubMed Central PMC10589831.
  9. Dennis, BB, Thabane, L, Heels-Ansdell, D, Dionne, JC, Binnie, A, Tsang, J et al.. Proton pump inhibitors in critically ill mechanically ventilated patients with COVID-19: protocol for a substudy of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial. Trials. 2023;24 (1):561. doi: 10.1186/s13063-023-07589-2. PubMed PMID:37644556 PubMed Central PMC10466724.
  10. Silversides, JA, McMullan, R, Emerson, LM, Bradbury, I, Bannard-Smith, J, Szakmany, T et al.. Correction: Feasibility of conservative fluid administration and deresuscitation compared with usual care in critical illness: the Role of Active Deresuscitation Correction: After Resuscitation-2 (RADAR-2) randomised clinical trial. Intensive Care Med. 2023;49 (11):1440. doi: 10.1007/s00134-023-07174-w. PubMed PMID:37642672 .
Search PubMed

Affiliations & Other Activities

  • Scientist, Keenan Research Centre for Biomedical Science
  • Trauma Surgeon and Intensivist, St. Michael’s Hospital
  • Professor, Department of Surgery, University of Toronto